The company’s founders defined the company through its name, ‘Akonni’ (of Native American origin). Akonni translates to “an attraction to the mysteries of nature, with a deep desire to understand those mysteries.”
Our mission is to develop, manufacture, and sell molecular diagnostic (MDx) tools for rapid, affordable and accurate diagnoses that will measurably improve the health status of millions of people worldwide.
Our vision is to build a flexible diagnostic platform and common manufacturing infrastructure (low cost and scalable) for our microarray products, which enables multiplexed pattern recognition of genetic, protein, metabolite or small molecule markers associated with the host or pathogen.
Akonni’s solutions are designed to address the following healthcare applications:
© 2003-2019 Akonni Biosystems, Inc. All rights reserved. Terms and Conditions • Privacy Policy
TruDiagnosis Systems, TruDx Readers, TruArray Tests, TruTip Kits, Primers, Lysis and Binding Buffers, Wash Buffers and Elution Buffers: For Research Use Only. Not for use in diagnostic procedures. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.
Based on its recent analysis of the microarrays in molecular diagnostics (MDx) market, Frost & Sullivan recognizes Akonni Biosystems with the 2017 North American New Product Innovation Award.
Akonni’s integrated MDx system, TruDiagnosis®, is revolutionizing the point-of-care molecular testing market by enabling target detection from a variety of sample types. TruDiagnosis® is powered by TruArray®, a patented 3D gel-drop microarray technology for sample screening that instantly indicates the presence of disease markers in real time.
Download: